Key Highlights

  • Navan shares are sharply lower, giving back a chunk of their recent rally.
  • Investors are growing cautious about execution risks tied to integrating the recently acquired Smartrips business.
  • Kuehn Law disclosed a shareholder litigation investigation alleging Navan misrepresented growth metrics ahead of its November 2025 IPO.
  • Wall Street remains broadly bullish, with Morgan Stanley recently raising its target to $50.

Navan shares are sharply lower, giving back a chunk of their recent rally as investors grow cautious about execution risks tied to integrating the recently acquired Smartrips business, with profit-taking accelerating after the stock hit a 52-week high earlier this week.

What Happened

Sentiment is further pressured by a newly disclosed shareholder litigation investigation from Kuehn Law alleging Navan misrepresented growth metrics and sales and marketing spend ahead of its November 2025 IPO.

This follows Navan's fiscal Q1 beat showing 39.8% year-over-year revenue growth and a surprise EPS profit.

Market Reaction

Even as Wall Street remains broadly bullish, with a Moderate/Strong Buy consensus and an average target of roughly $29-30, and Morgan Stanley recently raising its target to $50, continued insider selling by executives and major shareholders like Lightspeed Venture Partners adds to near-term caution.

Outlook

Despite the near-term caution, the company's roughly 30% revenue growth guidance for fiscal 2027 underscores its strong underlying growth trajectory.

Why are Navan shares falling sharply?

Shares fell on investor caution about Smartrips integration risk and a newly disclosed shareholder litigation investigation from Kuehn Law.

What does the Kuehn Law investigation allege?

That Navan misrepresented growth metrics and sales and marketing spend ahead of its November 2025 IPO.

What is Wall Street's outlook on Navan?

A Moderate/Strong Buy consensus with an average target of roughly $29-30, with Morgan Stanley recently raising its target to $50.